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Background: Many patients with childhood-onset growth hormone (GH) deficiency do not fulfill diagnostic criteria
for GH deficiency (GHD) after attainment of adult height and may not require long-term GH treatment. Patients
with history of idiopathic GHD (IGHD) pose the greatest management dilemma, as data regarding factors predictive
of persistent GHD in this group are lacking.
Objectives: The objective of this study was to assess potential predictors of persistent GHD in a US patient cohort
during transition from childhood to adulthood, particularly in patients with history of IGHD.
Methods: We studied 73 US patients with history of childhood-onset GHD screened at 21 US pediatric endocrine
centers for a randomized clinical trial of GH replacement after attainment of adult height. The cohort comprised 42
boys/men and 31 girls/women aged14–22 years, who had received ≥1 year of GH treatment and had completed
linear growth. The main outcome measures were sensitivity, specificity, positive and negative predictive values (PPV,
NPV) of clinical and hormonal factors for persistent GHD (defined a priori in this study as peak GH < 5 μg/L).
Results: For the cohort as a whole, the best predictors of persistent GHD (100% PPV) were history of organic
hypothalamic-pituitary disorder or ≥2 additional pituitary hormone deficiencies (PHD). Best predictors of persistent
GHD in patients with childhood history of IGHD were standard deviation scores (SDS) for serum insulin-like growth
factor binding protein-3 (IGFBP-3) below −2.0, and for insulin-like growth factor-I (IGF-I) below −5.3 (measured ≥6
weeks after completion of GH treatment; PPV 100% for both), and age <4 years at original diagnosis (PPV 89%). IGF-
I above −1.6 SDS had 100% NPV.
Conclusions: US patients with an organic cause of childhood-onset GHD or ≥2 additional PHDs may not require
GH stimulation testing to reconfirm GHD after completion of childhood treatment. In contrast, patients with
idiopathic childhood-onset GHD almost invariably require retesting, as GHD persists in only a minority (those who
were very young at initial diagnosis and those who have subnormal IGFBP-3 or extremely low IGF-I after
completion of childhood treatment). Subnormal posttreatment IGF-I (<−2.0 SDS) lacked predictive power for
persistent GHD, whereas IGF-I > −1.6 SDS was 100% predictive of GH sufficiency.
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Growth hormone (GH) treatment of patients with GH
deficiency (GHD) diagnosed in childhood has historic-
ally focused on maximizing adult height. However, this
limited goal overlooks the importance of GH for com-
pletion and maintenance of somatic and metabolic mat-
uration, including bone mineralization; accrual of lean
body mass, with accompanying increases in muscle
strength and exercise capacity; and changes in lipid
metabolism [1-18]. Thus, there is now consensus that
GH replacement is important for those patients with
childhood-onset GHD who remain GH deficient after
completion of linear growth [18-22].
Pharmacologic GH stimulation testing is generally
recommended to confirm the diagnosis of persistent
GHD during the childhood-to-adulthood transition, but
this procedure requires interruption of GH therapy, is
labor intensive, and is logistically challenging, given the
scarcity of testing agents now available. In addition, pro-
vocative testing is invasive, has the potential for signifi-
cant side effects, and produces inconsistent results that
do not predict treatment response [19-24]. Because of
these issues, several European studies have examined
clinical and biochemical predictors of persistent GHD
[25-30]. However, interpretation of the data is affected
by factors such as the retrospective nature of most
studies, interstudy differences in diagnostic criteria, and
interassay variability. Furthermore, because previous
studies have been performed in Europe, where diagnos-
tic and treatment practices differ from US practices, the
existing data may not be directly applicable to the largest
group of children treated in the USA—those with idio-
pathic GHD (IGHD). Therefore, this study determined
the prevalence of persistent GHD after attainment of
adult height in a cohort of US childhood-onset GH-
deficient patients during the transition period, with par-
ticular focus on those with IGHD, and examined the




This study screened 73 patients at 21 US institutions for
entry to a randomized clinical trial of GH effects on bone
and body composition in previously treated childhood-
onset GH-deficient patients (efficacy and safety data have
been reported [12,15]). The study was approved by the in-
stitutional review boards of participating institutions, and
written informed consent was obtained from patients and/
or their legal guardians.
Study entry criteria included: age 14–28 years; diagnosis
of GHD during childhood/adolescence (either idiopathic
or organic [i.e. due to a genetic or structural cause]); GH
treatment ≥1 year, completed 6 weeks–5 years beforescreening; attainment of adult height (height velocity <1
cm/year); no history of spinal or total body irradiation, bone
dysplasia, or significant systemic illness. Patients with add-
itional pituitary hormone deficiencies (PHDs) were required
to have received stable replacement therapy (thyroxine,
glucocorticoids, sex steroids, vasopressin, as needed) for ≥6
months. The US cohort from this international study was
selected for the analysis reported here because serum GH,
insulin-like growth factor-I (IGF-I), and insulin-like growth
factor binding protein-3 (IGFBP-3) concentrations for all
US patients were measured at a central laboratory.
Baseline demographic data included etiology and age
at diagnosis of childhood GHD, duration of previous GH
treatment, presence of additional PHDs, age, and height
and weight at retesting.
Assessment of GH secretion
Screening for entry to the adult GH replacement trial
included IGF-I and IGFBP-3 measurements followed by
GH stimulation testing. A single stimulation test was
sufficient for patients with history of multiple PHDs
(MPHD); 2 tests were required for patients with history
of isolated GHD. Protocol-preferred stimulation tests
included insulin tolerance test (ITT), combined argin-
ine/L-dopa test, and glucagon test. However, to repre-
sent the breadth of US pediatric endocrine practice, no
specific testing protocol was mandated. Patients were eli-
gible to enroll in the GH replacement trial if IGF-I was
<1st percentile for age/sex and peak GH was <5 μg/L.
The GH threshold for definition of GHD was specified
a priori in the protocol and is consistent with guidelines
for diagnosis of GHD during the transition period
[19-21]. Data from all US patients are included in this
report, regardless of eligibility for the GH replacement
trial.
Laboratory analyses
IGF-I was measured by an IGFBP-blocked radioimmuno-
assay as described elsewhere (sensitivity 0.1 μg/L; intra-
and interassay coefficients of variation [CV], 1.6% and
6.4%, respectively [31]). IGFBP-3 was measured by radio-
immunoassay (sensitivity 0.13 mg/L; intra- and interassay
CV, 1.9% and 9.2%, respectively [32]). Results were
converted to standard deviation scores (SDS) using data
for age/sex-matched controls from the same assays. GH
was measured using an immunochemiluminometric assay
specific for 22-kDa human GH [33]. All assays were
performed centrally at Esoterix Endocrinology, Inc
(Calabasas Hills, CA, USA).
Statistical analyses
Statistical analyses were performed using the SAS soft-
ware system (SAS Institute, Inc, Cary, NC). Because
stimulated GH values were not normally distributed, the
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differences between GH-deficient vs. non–GH-deficient
patients with respect to number of additional PHDs,
serum IGF-I/IGFBP-3, age at original diagnosis, weight,
and body mass index (BMI; kg/m2). The difference in
peak GH among patients with 0, 1, ≥1, or ≥2 PHDs was
examined using the nonparametric Kruskal-Wallis test.
Relationships between peak GH and potential explana-
tory variables were assessed using Spearman correlation
coefficients (rs). Summary data for continuous variables
are presented as mean ± SD unless otherwise noted.
Calculation of sensitivity, specificity, positive predictive
value, and negative predictive value
Sensitivity, specificity, positive predictive value (PPV),
and negative predictive value (NPV) were calculated to
determine the utility of clinical and laboratory variables
as screening tests for persistent GHD (defined as peak
GH response <5 μg/L). Screening variables included eti-
ology of childhood GHD (organic vs. idiopathic), age at
childhood diagnosis, number of additional PHDs, and
study entry values for weight, BMI, IGF-I, and IGFBP-3.
Continuous variables (age, weight, BMI, IGF-I, and
IGFBP-3 SDS) were tested to determine cut-off values
predictive of GHD. Patients with values beyond the cut-
off were classified as having a positive screening test
(screen) for GHD. Patients with a positive screen who
had maximum GH < 5 μg/L were designated as true
positive (TP); patients with a positive screen who hadTotal Pa
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Figure 1 Participant flow diagram. Participant flow diagram of patients i
idiopathic GH deficiency, multiple pituitary hormone deficiencies vs. isolate
retesting. F = female; GH = growth hormone; M = male; N = number of papeak GH ≥ 5 μg/L were designated false positive (FP); a
negative screen accompanied by peak GH ≥ 5 μg/L was
defined as true negative (TN); a negative screen with
peak GH < 5 μg/L was defined as false negative (FN).
The following additional definitions were used: sensitiv-
ity (of the screening test), represent the probability of a
positive screen among patients with GHD (i.e. proportion
of GH-deficient patients correctly identified by the screen,
calculated as TP/[TP + FN]); specificity, the converse of
sensitivity, represents the probability of a negative screen
among non–GH-deficient patients (proportion of non–
GH-deficient patients correctly identified by the screen;
TN/[TN + FP]); PPV, is the probability of GHD among
patients with a positive test (proportion of patients with
positive screen who were GH deficient; TP/[TP + FP]);
NPV, is the probability of being non-GH deficient among
patients with a negative screen (proportion of patients
with negative screen who were non–GH deficient; TN/
[TN + FN]). These calculations were determined for all
patients (organic and idiopathic combined) and repeated
separately for patients with IGHD.
Results
Historical and demographic data
Of 73 patients (42 male, 31 female; ages 13.7–22.4 years),
18 had history of organic GHD, and 55 had history of
IGHD (Figure 1, Table 1). Organic causes of GHD inclu-
ded craniopharyngioma (n = 6), glioma (n = 3), astrocytoma
(n = 2), germinoma (n = 2), cranial irradiation (n = 2); 1tients
2; F:31)
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Table 1 Demographic and diagnostic data
GHD at retest (peak GH <5 μg/L) Non-GHD at retest* p values**
Variable Organic n = 18
(M:9; F:9)
Idiopathic n = 20
(M:13; F:7)
Total n = 38
(M:22; F:16)






n (%) patients with
isolated GH deficiency
4 (22) 7 (35) 11 (29) 62 (89)
Age at diagnosis (yr)1 10.0 ± 2.2 4.5 ± 3.2 7.1 ± 3.9 10.5 ± 3.3 <0.001 <0.0001
10.6 (6.3, 13.7) 4.6 (0.1, 11.6) 7.2 (0.1, 13.7) 11.0 (2.2, 16.9)
Age at retest (yr) 17.9 ± 2.2 17.6 ± 1.8 17.7 ± 2.0 17.0 ± 1.6 0.08 0.17
18.2 (14.1, 22.4) 17.6 (13.7, 21.9) 17.6 (13.7, 22.4) 16.7 (14.1, 20.2)
Duration of childhood
GH treatment (yr) 1
5.6 ± 2.9 11.4 ± 3.6 8.6 ± 4.4 5.5 ± 2.8 <0.01 <0.0001
4.6 (2.0, 11.8) 12.2 (3.1, 16.7) 8.1 (2.0, 16.7) 4.7 (1.4, 12.7)
Time off GH (yr) 1.7 ± 1.6 1.5 ± 1.0 1.6 ± 1.3 0.9 ± 0.6 0.01 <0.01
1.2 (0.1, 5.0) 1.4 (0.2, 4.2) 1.3 (0.1, 5.0) 0.7 (0.2, 2.2)
Weight (kg) 76.9 ± 18.8 75.5 ± 19.7 76.2 ± 19.0 60.5 ± 10.0 <0.001 <0.01
74.6 (44.9, 119.3) 69.8 (47.1, 110.5) 74.2 (44.9, 119.3) 59.2 (42.5, 82.4)
BMI (kg/m2) 27.5 ± 6.2 26.4 ± 5.5 26.9 ± 5.8 21.9 ± 2.9 <0.001 <0.01
26.8 (15.1, 37.4) 26.2 (18.6, 37.4) 26.2 (15.1, 37.4) 21.0 (16.6, 29.8)
BMI SDS 0.9 ± 1.6 0.9 ± 1.2 0.9 ± 1.4 0.1 ± 0.9 <0.001 <0.01
1.4 (−4.4, 2.5) 1.4 (−1.8, 2.5) 1.4 (−4.4, 2.5) 0.2 (−2.3, 1.9)
Number of additional
PHDs
2.3 ± 1.7 1.5 ± 1.4 1.9 ± 1.6 0.0 ± 0.2 <0.0001 <0.0001
2.5 (0.0, 4.0) 1.5 (0.0, 4.0) 2.0 (0.0, 4.0) 0.0 (0.0, 1.0)
Peak GH (μg/L) 0.7 ± 0.9 0.5 ± 0.6 0.6 ± 0.8 15.2 ± 10.1 <0.0001 <0.0001
0.2 (0.1, 3.0) 0.3 (0.0, 2.2) 0.2 (0.0, 3.0) 13.0 (5.0, 57.0)
IGF-I (μg/L) 100 ± 67 123 ± 78 112 ± 73 309 ± 123 <0.0001 <0.0001
86 (30, 265) 95 (20, 248) 93 (20, 265) 295 (117, 738)
IGF-I SDS −6.2 ± 2.4 −5.7 ± 2.7 −6.0 ± 2.5 −1.9 ± 1.4 <0.0001 <0.0001
−6.0 (−9.8, –1.6) −5.8 (−11.1, –1.6) −5.8 (−11.1, –1.6) −2.0 (−5.3, 1.5)
IGFBP-3 (μg/L) 2.5 ± 1.0 2.8 ± 1.3 2.7 ± 1.2 3.8 ± 0.7 <0.0001 <0.01
2.5 (1.1, 4.5) 2.4 (1.1, 5.9) 2.5 (1.1, 5.9) 3.8 (2.5, 5.4)
IGFBP-3 SDS −1.4 ± 1.6 −1.2 ± 1.9 −1.3 ± 1.7 0.4 ± 0.8 <0.0001 <0.01
−1.3 (−4.5, 1.2) −1.4 (−4.6, 2.4) −1.3 (−4.6, 2.4) 0.4 (−1.2, 1.9)
Values are means ± SD and median (minimum, maximum). *All patients who retested as non-GH deficient had idiopathic GH deficiency in childhood. **p values
for comparisons of groups who were GH deficient vs. non-GH-deficient at retest were obtained from nonparametric Wilcoxon tests. 1Comparisons between
organic vs. idiopathic patients with GHD at retest: p < 0.0001 for age at diagnosis and duration of childhood GH treatment; all others, nonsignificant.
Abbreviations: BMI = body mass index, F = female, GH = growth hormone, GHD = GH deficiency, IGF-I = insulin-like growth factor I, IGFBP-3 = insulin-like growth
factor binding protein 3, kg = kilogram, M = male, m2 = meters squared, n = number, PHDs = pituitary hormone deficiencies, SDS = standard deviation score,
yr = year.
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dysplasia, and pituitary hypoplasia.
Twenty-eight of 73 patients (38%) had ≥1 additional
PHD (14/18 [78%] organic; 14/55 [25%] idiopathic). In
order of prevalence these were: thyroid-stimulating hor-
mone (TSH, n = 25 [34%]); gonadotropins (n = 20 [27%]);
adrenocorticotropic hormone (n = 17 [23%]); vasopressin
(n = 10 [14%]). Eight patients (11%) had 1 additional
PHD, 5 (7%) had 2 additional PHDs, 6 (8%) had 3 add-
itional PHDs, and 9 (12%) had 4 additional PHDs. The
relationship between additional PHDs and likelihood of
persistent GHD is reported below.GH stimulation retest results
The following GH stimulation tests were performed: ar-
ginine/L-dopa (48/73 [66%]); arginine alone (11/73
[15%]); ITT alone (7/73 [10%]); ITT/arginine (3/73
[4%]); 1 patient each was tested with ITT/clonidine,
ITT/L-dopa, L-dopa alone, and an unspecified test. As
shown in Figure 1 and Table 1, 38 of 73 patients had
peak GH <5 μg/L at retest (male, 22/42 [52%]; female,
16/31 [52%]; organic, 18/18 [100%]; idiopathic, 20/55
[36%]); 37/38 (97%) patients with persistent GHD had
severe GHD, with peak GH <2.5 μg/L. Of 20 patients
































0.3* 0.1* 0.1* 0.1*
Figure 2 Peak GH response according to number of additional pituitary hormone deficiencies (PHD). Horizontal lines represent the
median values of the peak stimulated GH concentrations for patients with 0, 1, 2, 3, and 4 additional PHDs; *p < 0.0001 for comparison of
medians for the group with isolated GH deficiency (no additional PHDs) vs. all others. See “Results” for listing of stimulation tests used. #To avoid
compressing the vertical axis, 1 GH value of 57 μg/L (idiopathic patient) is not shown. GH = growth hormone; N = total number of patients in
each category (organic vs. idiopathic); n = number of patients in each subgroup.
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GH values >1.0 μg/L at retest (1.5, 1.6, 2.2 μg/L). Patients
with persistent GHD were younger at original diagnosis
than those not reconfirmed as GH deficient, and at
screening were significantly heavier and had lower
posttreatment serum IGF-I and IGFBP-3 (Table 1).
Predictors of persistent GH deficiency
All patients
The strongest predictor of persistent GHD was history
of organic hypothalamic-pituitary disorder: 18/18 or-
ganic patients retested as GH deficient (100% PPV) vs.
20/55 (36%) of those with history of IGHD. However,
sensitivity was low (47%) because history of IGHD did
not preclude persistent GHD.
The second highly predictive finding was the presence of
additional PHDs (Figure 2, Table 2). Of 28 patients with ≥1
additional PHD, 27 (96%) had GH < 5 μg/L at retest (13/
14 [93%] idiopathic, 14/14 [100%] organic). Overall, GHD
was reconfirmed in 24%, 88%, 96%, and 100% of patients











100 100 96 100
Negative Predictive
Value (%)
64 66 76 71
Specificity (%) 100 100 97 100
Sensitivity (%) 47 53 71 63
Abbreviations: IGF-I = insulin-like growth factor I, IGFBP-3 = insulin-like growth factor
standard deviation score.100% for ≥2 PHDs; Table 2). Peak stimulated GH (μg/L)
was significantly lower in patients with ≥1 additional PHD
than in those with isolated GHD (mean ± SD, median,
range: 0.7 ± 1.8, 0.1, 0.0–9.0; vs. 11.9 ± 10.8, 9.2, 0.0–57.0;
p < 0.001). However, presence of additional PHDs was not
an essential feature of persistent GHD, as almost one-
quarter of patients with history of isolated GHD had per-
sistent GHD (overall, 11/45 [24%]; organic, 4/4 [100%];
idiopathic, 7/41 [17%]: Figure 1). As a corollary, 11/38
patients (29%) with reconfirmed GHD had childhood his-
tory of isolated GHD (organic and idiopathic combined).
Because history of organic hypothalamic-pituitary dis-
order had 100% PPV for persistent GHD during transition,
results for predictive value of IGF-I SDS, IGFBP-3 SDS, age
at original diagnosis, body weight, and BMI are presented
below only for the 55 patients with history of IGHD.
Patients with idiopathic GH deficiency
IGF-I and IGFBP-3 As reported above, 20 of 55 (36%)







≥1 extra PHD and
IGF-I < −2.0 SDS
IGFBP-3 <
−2.0 SDS
84 65 100 100
83 84 75 59
83 46 100 100
84 92 68 37
binding protein 3, n = number, PHD = pituitary hormone deficiency, SDS =
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(both as absolute values and as SDS) in patients with peak
GH < 5 μg/L (Table 1); however, the range of IGF-I SDS
values was wide (−1.6 to −11.1; Table 1, Figure 3a). Mean
IGF-I SDS was lower for female than for male patients
with persistent GHD (−7.68 ± 2.54 vs. −4.65 ± 2.19,
p = 0.04). There was a strong correlation between IGF-I
SDS and peak GH (n = 54, rs = 0.67, p < 0.0001) primar-
ily driven by the lower IGF-I SDS values. For idiopathic
patients with peak GH < 5 μg/L at retest, the correlation
was modest but did not quite reach statistical signifi-
cance: n = 20, rs = 0.43, p = 0.06; for those with GH ≥
5 μg/L the correlation was lower and non-significant:
n = 34, rs = 0.20, p = 0.26.
Although two thirds of patients with history of IGHD
(36/54 [67%]; value missing for 1 patient) had subnormal
serum IGF-I (<−2.0 SDS) at retesting, this threshold did
not discriminate well between those who retested with
peak GH above (n = 35) or below (n = 20) 5 μg/L (speci-
ficity 50%; Table 3). Therefore, different threshold values
of IGF-I SDS were examined to determine the cut-off
that provided optimal predictive power. Whereas only
19/36 (53%) of idiopathic patients with IGF-I < −2.0
SDS had peak GH < 5 μg/L at retest, PPV increased to
73% at −3.0 SDS, 81% at −4.0 SDS, and 100% at −5.3
SDS (Table 3). However, at this very low cutoff, sensitiv-
ity was only 55% because 9 idiopathic patients who
retested as GH deficient had IGF-I SDS greater than this
threshold (Figure 3a). Notably, only 1 idiopathic patient
who retested as GH deficient had IGF-I > −2.0 SDS, and
none had IGF-I > −1.6 SDS; thus IGF-I > −1.6 SDS had
100% NPV for GHD (Table 3, Figure 3a).
In general, mean IGFBP-3 concentrations were closer
to average for age/sex than IGF-I in the idiopathic co-
hort (Table 1), but were somewhat lower for female
than male patients (for patients with persistent GHD:
female, −1.86 ± 2.39; male, −0.77 ± 1.56; p = 0.28). Sub-
normal IGFBP-3 was more predictive of persistent GHD
than subnormal IGF-I in this group, as all idiopathic
patients with IGFBP-3 < −2.0 SDS had peak GH < 5 μg/L
on retest (PPV 100%; Table 3, Figure 3b).
Age at original diagnosis Young age (<4 years) at diag-
nosis of childhood IGHD was a strong predictor of per-
sistent GHD in this group, with 97% specificity and
89% PPV (Table 3). On average patients with history of
IGHD who later retested as GH deficient were less than
half the age at original diagnosis of those who retested
as non–GH deficient (4.5 ± 3.2 vs. 10.5 ± 3.3 years,
p < 0.0001; Table 1, Figure 4). IGHD patients with per-
sistent GHD therefore had received GH treatment for
twice as long as those who retested as non–GH defi-
cient and those with organic GHD (Table 1).Sex, body weight, and BMI The proportion of patients
with history of IGHD who had persistent GHD at retest
was similar for male and female patients (13/33 [39%]
vs. 7/22 [32%]). Body weight and BMI at retest were sig-
nificantly greater in patients with persistent GHD than
in those with peak GH ≥ 5 μg/L (p < 0.01), demonstrat-
ing modest but significant inverse correlations with peak
GH (BMI vs. peak GH: n = 54, rs = −0.39, p = 0.003)
and with IGF-I SDS (BMI vs. IGF-I SDS: n = 54,
rs = −0.31, p = 0.02). Although there was a wide range
of BMI values (18.6–37.4 kg/m2) in idiopathic patients
with persistent GHD, all patients with BMI >30 kg/m2
had peak GH <5 μg/L at retest (Figure 3c).
Because overweight and obesity may blunt GH secre-
tion even in non–GH-deficient individuals, we specific-
ally evaluated all idiopathic patients who had GH
stimulation test results consistent with persistent GHD
and had BMI >25 kg/m2 (World Health Organization
definition of overweight) at retesting. Of 12 such
patients, 10 had additional PHDs, and therefore had in-
dependent factors strongly predictive of persistent GHD
(93% PPV), irrespective of BMI. The 2 overweight
patients with isolated IGHD whose GH responses could
potentially have been blunted by being overweight, were
only mildly overweight and had peak GH values <1μg/L
(patient 1: BMI 26 kg/m2, peak GH 0.70 μg/L; patient 2:
BMI 28 kg/m2, peak GH 0.26 μg/L). Therefore, given
these extremely low peak GH concentrations, it seems
unlikely that either of these patients was misclassified as
GH deficient due to obesity-related blunting of GH
secretion. Overall, neither weight nor BMI was a good
predictor of persistent GHD (e.g. PPV 36% for BMI
38 kg/m2).
Discussion
Since the early 1990s the role of GH in many physio-
logic processes in adulthood has become clearer, and
the importance of GH replacement for GH-deficient
adults is well established [19-21,34]. Many studies have
demonstrated deficits in somatic and metabolic matur-
ation in GH-deficient individuals untreated during the
transition period [1-4,6-17]. However, the determination
of precisely which patients require ongoing GH therapy
has been less clear, as many patients treated for child-
hood GHD do not fulfill diagnostic criteria for adult
GHD after completion of linear growth. This finding
may reflect a number of factors, including differences in
diagnostic criteria for GHD in childhood vs. adulthood,
lack of reproducibility of GH stimulation tests, and
perhaps sex steroid–mediated maturational changes in
hypothalamic control of GH secretion during puberty
[23,35-37]. Consequently, retesting GH secretion in
adolescents and young adults with childhood-onset
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Figure 3 a. Relationship between IGF-I SDS and peak GH response. Dashed vertical line represents the IGF-I threshold of −5.3 SDS, which
provides 100% PPV for the diagnosis of persistent GH deficiency in patients with IGHD. IGF-I = insulin-like growth factor –I; b. Relationship
between IGFBP-3 SDS and peak GH response. Dashed vertical line represents the IGFBP-3 threshold of −2.0 SDS, which provides 100% PPV for
the diagnosis of persistent GH deficiency in patients with IGHD. IGFBP-3 = insulin-like growth factor binding protein 3; c. Relationship between
body mass index and peak GH response. For the idiopathic group, Spearman r = −0.39, p = 0.003. There was no significant correlation for the
organic group. Notes and abbreviations: See “Results” for listing of stimulation tests used; #One outlier idiopathic patient with a peak GH of 57 μg/L
was excluded to avoid undue influence on the correlation and compressing the vertical axis. GH = growth hormone; IGHD = idiopathic GH
deficiency; N = total number of patients in each category (organic vs. idiopathic); PPV = positive predictive value; SDS = standard deviation score.
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83 78 79 82 88 94 100 73 76 83 75
Specificity (%) 97 100 100 91 82 50 38 100 97 100 100
Sensitivity (%) 65 50 55 65 80 95 100 35 42 65 40
Abbreviations: Dx = diagnosis, GH = growth hormone, IGF-I = insulin-like growth factor I, n = number, PHD = pituitary hormone deficiency, SDS = standard deviation
score, yr = year.
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results vary by protocol, secretagogue, and GH assay;
lack reproducibility; and do not predict treatment re-
sponse [23]. Furthermore, the increasingly limited avail-
ability of many agents for which GH stimulation testing
protocols are established (e.g. arginine, GH-releasing
hormone, L-dopa) leaves few options other than ITT,
which requires physician presence because of the risk of
complications such as seizures as a result of significant
hypoglycemia [24,33]. Therefore, this study aimed to
provide a rational basis for GH stimulation retesting in
US patients by examining factors predictive of persistent
GHD in a cohort of 73 patients with history of childhood-
onset GHD who underwent centralized measurements of
IGF-I, IGFBP-3, and GH after completion of childhood
treatment. Because of limited published information, par-
ticular attention was focused on factors predictive of per-
sistence in patients with history of IGHD, the most
common form of childhood GHD treated in the USA.µ
Figure 4 Age at original childhood diagnosis of GH deficiency. Distribu
deficient (left) vs. those who retested as GH sufficient (right). Within the persis
deficiency were significantly younger at diagnosis than those with history of o
initial diagnosis for patients with history of IGHD. GH = growth hormone; N =Our finding that 100% of US patients with history of
organic GHD had persistent GHD confirms previous
European reports [26,27,30,38,39]. Similarly, we found a
very high prevalence of persistent GHD in patients with
≥1 additional PHD (96% PPV) [25,29,40-42]. Thus it
appears that despite potential differences between US
and European physicians with regard to diagnosis and
treatment of childhood GHD, the key factors associated
with its persistence appear consistent across these geog-
raphies. The single patient with an additional PHD (TSH)
who did not fulfill the study definition of GHD may never-
theless have a partial GH secretory defect because peak
GH response to arginine/L-dopa was 9.0 μg/L. Other
studies have concluded that such patients may have a
milder form of GH “insufficiency” [29,43-45]. As GH is
usually the first anterior pituitary hormone affected by
pathological insults, there is a biological rationale to sus-
pect that patients with ≥1 additional PHD will likely
have persistent GHD [46,47].µ
tion of age at original diagnosis for patients who retested as GH
tently GH-deficient group, patients with history of idiopathic GH
rganic GH deficiency (Table 1). Horizontal lines represent mean ages at
total number of patients in each category (organic vs. idiopathic).
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PHDs reflect the severity of hypothalamic-pituitary
dysfunction, so it is not surprising that severe GHD
persisted in almost all such patients; provocative GH
retesting thus appears unnecessary in patients with or-
ganic disease [29,38,39,42]. Instead, GH potentially could
be continued uninterrupted through the transition
period (with appropriate dosage adjustment) to avoid
the adverse changes in body composition, lipid profile,
and cardiac function that may develop following discon-
tinuation of GH [1-4,6-17]. Furthermore, patient care
could potentially be improved by providing the family
with a clear expectation at the initiation of childhood
treatment, of the likelihood that GH treatment will be
required in adulthood.
Although only half of our patients with MPHD had a
childhood diagnosis of organic disease, some patients
whose MPHD was labeled “idiopathic” may, in fact, have
had an undiagnosed genetic disorder. This is suggested
in other studies by the presence of mutations in genes
encoding pituitary transcription factors, most commonly
PROP1, in up to half of patients with an original diagno-
sis of idiopathic MPHD [37,48-51]. Furthermore, up to
one-quarter of children with isolated GHD may have de-
tectable genetic defects [49,52,53]. Thus, genetic studies
should be obtained whenever possible in any patient
with MPHD or early-onset isolated GHD, because pres-
ence of a mutation would obviate the need for GH
stimulation retesting after childhood treatment, and
allow such patients to continue replacement therapy un-
interrupted. Similarly, although our study did not in-
clude magnetic resonance imaging (MRI) assessment,
MRI anomalies have been reported as a significant pre-
dictor of persistent GHD during transition [27,37,41,54],
and certain MRI findings may indicate a genetic basis
for hypothalamic-pituitary disorders [55-57].
In contrast to those with organic hypothalamic-
pituitary dysfunction, patients with childhood IGHD
present a substantial diagnostic dilemma, and prior stud-
ies have not evaluated predictive factors for persistent
GHD in this specific population. Moreover, as idiopathic
patients represent the majority of recipients of childhood
GH treatment in the USA [58-60], they constitute the
bulk of the clinical load for US pediatric endocrinologists.
Therefore, our study specifically examined factors pre-
dictive of persistent GHD in this subgroup. Only about
one-third of idiopathic patients (36%) retested as GH de-
ficient; this was true for even fewer patients with isolated
IGHD (17%). The low rate of persistent GHD in our
US idiopathic cohort is similar to the rates reported in
Belgian, British, and French studies, in which 15%–24%
patients with childhood isolated IGHD remained GH
deficient when retested [26,40,61]. However, our results
differ notably from those of an Italian study in which52%–65% of young adults with isolated IGHD were GH
deficient on retest, likely reflecting the fact that about
one-third of patients in the Italian study had severe child-
hood GHD [39].
Apart from the presence of additional PHDs, the
strongest independent predictor of persistent GHD in
our idiopathic cohort was the finding of IGFBP-3
below −2.0 SDS, which had 100% PPV for persistent GHD.
In contrast, a subnormal IGF-I value (i.e. <−2.0 SDS) was
not prognostically helpful in those with history of IGHD,
as only half of such patients retested as GH deficient.
However, an extremely low IGF-I (<−5.3 SDS) provided
100% PPV; in addition, the combination of IGF-I SDS
below −2.0 and young age at original diagnosis of IGHD
was strongly predictive of persistent GHD. Our finding
of lack of predictive power of subnormal IGF-I contrasts
with the good concordance between IGF-I and peak GH
reported in European studies [25-27,55], perhaps reflecting
the typically greater severity of GHD in European children,
differences in agents and diagnostic cut-points used for
GH testing, and time between discontinuation of GH and
retesting (as GHD may manifest after increasing time off
treatment [43,44]). Furthermore, IGF-I secretion is con-
trolled by other factors in addition to GH, such as nutri-
tional status and sex steroid milieu [32,62,63]. Perhaps
more importantly, IGF-I may provide a good screen for
GH sufficiency, as 100% of idiopathic patients who had
IGF-I > −1.6 SDS were GH sufficient on retest (100% NPV
for GHD). Patients with IGF-I SDS values above this level
after discontinuation of GH treatment could be spared the
invasive process of GH stimulation retesting after comple-
tion of childhood therapy, as all would be expected to be
GH sufficient, and instead could be followed clinically.
The other useful predictor of persistent GHD in the
idiopathic cohort was age <4 years at original diagnosis
(specificity 97%, PPV 89%), likely reflecting the fact that
growth failure occurs earlier in children with more se-
vere GHD [29]. Consequently, families of children who
are very young at initial diagnosis of IGHD should be
forewarned of the likelihood of its permanence.
This study has a number of potential limitations. First,
no direct comparison of GH stimulation test results at
the time of childhood diagnosis versus results on retest
in the present study could be made because initial
testing was performed at the individual institutions and
not at a central laboratory. For the same reason, we were
unable to assess the predictive value of a number of other
clinically relevant parameters, such as pretreatment IGF-I,
height SDS, height velocity, or height gain in response to
childhood treatment. Second, the single cut-point of
5 μg/L defined in the protocol to represent the threshold
for GH deficiency irrespective of the testing agent used,
may be considered to lack precision; a subsequent study
in patients with adult-onset GHD (conducted after our
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ferent diagnostic thresholds are appropriate for different
agents [33]. However, evidence for the appropriateness of
this approach is lacking for patients in the transition
period, as noted by consensus statements from endocrine
societies [19-21]. Third, because our study population
comprised patients screened for aGH replacement trial,
the cohort may represent the more severe end of the US
childhood GHD spectrum, and persistent GHD may be
less likely in milder cohorts. Nevertheless, our finding that
only 17% of patients with history of isolated IGHD had
persistent GHD is consistent with European data for
this subgroup. Fourth, IGF-I assays have substantial
interlaboratory variability, so the very low IGF-I SDS
values predictive of persistent GHD in our study may not
be applicable to IGF-I measured elsewhere. Fifth, obesity
is associated with blunted GH response to stimulation,
even in non–GH-deficient individuals [64], leading to
potential bias toward overdiagnosis of GHD. Thus the
peak GH threshold of 5 μg/L used for diagnosis of GHD
in this study may be inadequately stringent for obese
patients (BMI > 30 kg/m2) [20]. Nevertheless, as all
obese patients in this study had additional PHDs, mis-
diagnosis due to obesity-related blunting of GH secretion
seems unlikely. Finally, it is acknowledged that no single
study can provide comprehensive guidelines for the broad
range of patients treated and followed in different clinical
settings, and assessment should be individualized for each
patient.
Conclusions
This US study demonstrates that patients with an organic
basis for childhood-onset GHD and those with ≥2 add-
itional PHDs may not require GH stimulation testing after
completion of linear growth for confirmation of persistent
GHD and potentially could continue GH treatment with-
out interruption. However, as most children treated in the
USA have an idiopathic, isolated form of GHD, the major-
ity will likely not require GH treatment during adulthood.
In patients with history of IGHD, the strongest predictor
of persistent GHD was subnormal IGFBP-3 SDS (<−2.0
SDS), whereas subnormal IGF-I (<−2.0 SDS) lacked pre-
dictive power. Conversely, posttreatment IGF-I > −1.6
SDS was predictive of GH sufficiency. Therefore, unless
IGF-I is extremely low (<−5.3 SDS) accompanied by sub-
normal IGFBP-3 (<−2.0 SDS), patients with IGHD should
undergo GH retesting after completion of childhood
treatment.
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